David White

Ed Arce

Len Levi

Sa'ar Yaniv

Thomas Yip

Vernon Bernardino

- Galectin Therapeutics presented on **palipectin**, its lead compound, a galectin-3 inhibitor in development for patients with **MASH cirrhosis and portal hypertension**.  **[0001133416_2193152_1]** 
- In the Phase 2B Navigate trial, palipectin at **2 mg significantly reduced the incidence of new varices** at 18 months in the per protocol population.  **[0001133416_2193152_2]** 
- Palipectin demonstrated a **favorable safety profile**, with low discontinuation rates due to adverse events and no drug-related serious adverse events reported.  **[0001133416_2193152_4]** 
- The company is now focused on **advancing discussions with regulatory agencies** and identifying a partner to move the program forward.  **[0001133416_2193152_4]**

Galectin Therapeutics Presents Promising Clinical Data for Palipectin in MASH Cirrhosis

- Galectin Therapeutics presented its lead compound, **palapectin**, a proprietary galectin-3 inhibitor, for patients with **MASH cirrhosis and portal hypertension** at the H.C. Wainwright Virtual Liver Disease Conference.  **[0001133416_2193199_1]** 
- In the NAVIGATE trial, **palapectin 2 mg significantly reduced the incidence of new varices at 18 months** in the per protocol population of patients with compensated MASH cirrhosis and portal hypertension.  **[0001133416_2193199_2]** 
- The 2 mg dose also reduced the incidence of medium or large-sized varices, which are more prone to bleeding.  **[0001133416_2193199_2]** 
- Palapectin demonstrated a **favorable safety profile**, with no drug-related serious adverse events reported in the trial.  **[0001133416_2193199_3]** 
- The company is now focused on discussions with regulatory agencies and identifying a partner to advance the program.  **[0001133416_2193199_4]**

Galectin Therapeutics Presents Promising Palapectin Data for MASH Cirrhosis at H.C. Wainwright Conference

- Galimedix Therapeutics has **completed its Phase 1 study** for orally administered **GAL-101**, a small molecule designed to target misfolded amyloid beta monomers.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** 
- The study demonstrated that oral GAL-101 was **well tolerated and clinically safe**, with no serious adverse events, and effectively **crosses the blood-brain barrier**.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_0]** 
- The pharmacokinetic profile strongly supports advancing GAL-101 into **Phase 2 development for Alzheimer’s disease**, with a Phase 2 trial planned and fundraising initiated.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_0]** 
- Additionally, Galimedix is conducting a **partner-funded Phase 2 clinical trial** with GAL-101 eyedrops for dry age-related macular degeneration (dAMD).  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_3]**

GALECTIN THERAPEUTICS (GALT)